Cargando…

In Vivo PET Imaging of Monocytes Labeled with [(89)Zr]Zr-PLGA-NH(2) Nanoparticles in Tumor and Staphylococcus aureus Infection Models

SIMPLE SUMMARY: Immune cells are increasingly used for therapy in cancer and other diseases. To better understand immune-cell kinetics, cell-tracking with highly sensitive imaging modalities is required. The aim of this study was to develop a new strategy for the in vivo tracking of a small number o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krekorian, Massis, Cortenbach, Kimberley R. G., Boswinkel, Milou, Kip, Annemarie, Franssen, Gerben M., Veltien, Andor, Scheenen, Tom W. J., Raavé, René, van Riessen, Nicolaas Koen, Srinivas, Mangala, de Vries, Ingrid Jolanda M., Figdor, Carl G., Aarntzen, Erik H. J. G., Heskamp, Sandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533969/ https://www.ncbi.nlm.nih.gov/pubmed/34680219 http://dx.doi.org/10.3390/cancers13205069

Ejemplares similares

Characterization of Intrinsically Radiolabeled Poly(lactic-co-glycolic acid) Nanoparticles for ex Vivo Autologous Cell Labeling and in Vivo Tracking
por: Krekorian, Massis, et al.
Publicado: (2021)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

Imaging of T-cells and their responses during anti-cancer immunotherapy
por: Krekorian, Massis, et al.
Publicado: (2019)

Click-to-Release: Cleavable Radioimmunoimaging with [(89)Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio
por: Vlastara, Maria, et al.
Publicado: (2023)

Toward Optimized (89)Zr-Immuno-PET: Side-by-Side Comparison of [(89)Zr]Zr-DFO-, [(89)Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [(89)Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
por: Damerow, Helen, et al.
Publicado: (2022)

Comparative in vivo biodistribution of cells labelled with [(89)Zr]Zr-(oxinate)(4) or [(89)Zr]Zr-DFO-NCS using PET
por: Friberger, Ida, et al.
Publicado: (2023)

Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET
por: Raavé, René, et al.
Publicado: (2019)

(89)Zr-immuno-PET using the anti-LAG-3 tracer [(89)Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
por: Miedema, Iris H.C., et al.
Publicado: (2023)

Lesion detection by [(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2019)

[(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma
por: Verhoeff, Sarah R., et al.
Publicado: (2023)

Additional information on “Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET”
por: Raavé, René, et al.
Publicado: (2019)

Novel Bifunctional Cyclic Chelator for (89)Zr Labeling–Radiolabeling and Targeting Properties of RGD Conjugates
por: Zhai, Chuangyan, et al.
Publicado: (2015)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Optimisation of the Synthesis and Cell Labelling Conditions for [(89)Zr]Zr-oxine and [(89)Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2021)

Correction: Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
por: Friberger, Ida, et al.
Publicado: (2022)

Förster Resonance Energy Transfer-Based Stability Assessment of PLGA Nanoparticles in Vitro and in Vivo
por: Swider, Edyta, et al.
Publicado: (2019)

Current Perspectives on (89)Zr-PET Imaging
por: Yoon, Joon-Kee, et al.
Publicado: (2020)

[(89)Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates
por: Rosar, Florian, et al.
Publicado: (2022)

Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
por: Marquez, Bernadette V., et al.
Publicado: (2014)

Heptadentate chelates for (89)Zr-radiolabelling of monoclonal antibodies
por: Guillou, Amaury, et al.
Publicado: (2022)

Development and evaluation of (89)Zr-trastuzumab for clinical applications
por: Mohammadpour-Ghazi, Fatemeh, et al.
Publicado: (2023)

(89)Zr-Onartuzumab PET imaging of c-MET receptor dynamics
por: Pool, Martin, et al.
Publicado: (2017)

PET Imaging of Small Extracellular Vesicles via [(89)Zr]Zr(oxinate)(4) Direct Radiolabeling
por: Khan, Azalea A., et al.
Publicado: (2022)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Exploiting the Concept of Multivalency with (68)Ga- and (89)Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression
por: Summer, Dominik, et al.
Publicado: (2018)

Biodistribution of Mesenchymal Stromal Cells Labeled with [(89)Zr]Zr-Oxine in Local Radiation Injuries in Laboratory Animals
por: Astrelina, Tatiana A., et al.
Publicado: (2023)

(19)F MRI Imaging Strategies to Reduce Isoflurane Artifacts in In Vivo Images
por: Staal, Alexander H. J., et al.
Publicado: (2021)

Annotating MYC oncogene status with (89)Zr-transferrin imaging
por: Holland, Jason P., et al.
Publicado: (2012)

Microfluidic Preparation of (89)Zr-Radiolabelled Proteins by Flow Photochemistry
por: Earley, Daniel F., et al.
Publicado: (2021)

Immuno-PET Imaging of Atherosclerotic Plaques with [(89)Zr]Zr-Anti-CD40 mAb—Proof of Concept
por: Poels, Kikkie, et al.
Publicado: (2022)

(89)Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors
por: Chang, Albert J., et al.
Publicado: (2012)

(89)Zr-cetuximab PET imaging in patients with advanced colorectal cancer
por: Menke-van der Houven van Oordt, Catharina Willemien, et al.
Publicado: (2015)

(89)Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations
por: Kahts, Maryke, et al.
Publicado: (2023)

Pyruvate‐lactate exchange and glucose uptake in human prostate cancer cell models. A study in xenografts and suspensions by hyperpolarized [1‐(13)C]pyruvate MRS and [(18)F]FDG‐PET
por: van Heijster, Frits H.A., et al.
Publicado: (2020)

Applying (89)Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins
por: Doran, Michael G., et al.
Publicado: (2016)

(89)Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs
por: van der Veen, Elly L, et al.
Publicado: (2020)

In Vitro and In Vivo Comparison of Selected Ga-68 and Zr-89 Labelled Siderophores
por: Petrik, Milos, et al.
Publicado: (2015)

Development of (89)Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications
por: Lange, Sara E.S., et al.
Publicado: (2016)

Evaluation of Candidate Theranostics for (227)Th/(89)Zr Paired Radioimmunotherapy of Lymphoma
por: Abou, Diane S., et al.
Publicado: (2023)

Re-Evaluations of Zr-DFO Complex Coordination Chemistry for the Estimation of Radiochemical Yields and Chelator-to-Antibody Ratios of (89)Zr Immune-PET Tracers
por: Imura, Ryota, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_unn37evkv5ru6i36d4f0loo8d1